GUTTMAN-YASSKY, E. .; WEIDINGER, S. .; SIMPSON, E. .; GOODERHAM, M. .; IRVINE, A. .; SPELMAN, L. .; SILVERBERG, J. .; ELMARAGHY, H. .; DELUCA-CARTER, L. .; BUZIQUI PIRUZELI, M. L. .; HU, C. .; YANG, F. E. .; PIERCE, E. .; BARDOLET, L. .; THACI, D. . Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s271, 2023. DOI: 10.25251/skin.7.supp.271. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/2382. Acesso em: 3 jul. 2024.